SMi Presents the 3rd Annual Conference: Injectable Drug Delivery 2020

SMi Group 13 - 14 May 2020, London, UK.
SMi Group is pleased to announce the third annual Injectable Drug Delivery conference, which will be held in London. Part of Europe's leading Injectable conference series, Injectable Drug Delivery will assess innovations in drug product formulation and biologics, innovations in device design, quality management and connectivity for enhanced subcutaneous delivery.

With rapid developments in the parenteral space, the injectable drug delivery market is set to reach USD 902.3 billion by 2027, with an increased focus on patient centricity during DDC development and innovations in device development, including new therapeutic applications such as the delivery of siRNA. This year's event will focus on advances in drug product formulation and innovations of device design and development to aid delivery.

Furthermore, the conference will assess the evolving regulatory environment of injectable drug delivery with industry and regulatory representatives presenting updates on current guidelines.

The two-day agenda also offers peer-to-peer networking with Global Product Managers, Device Testing Managers, Senior Device Engineers, Heads of Device Development, Heads of Formulation and Drug Process Development, and many more.

The benefits of attending

This conference offers a chance to learn about innovative injectable drug delivery systems with industrial insights on the following:
  • DELVE into the latest work in complex formulation for subcutaneous delivery
  • BENCHMARK against leading pharma companies working to enhance device design and development
  • UNDERSTAND the regulatory environment of the injectables space from leading regulatory and industry advisors
  • ENGAGE in industry case studies on design controls, human factors and parenteral formulation
  • EXPLORE advances in connectivity and human factors key learnings in two pre-conference workshops

Who should attend

Executives, Directors, VPs, Heads, Principals, Managers, Scientists, Researchers of:
  • Autoinjectors
  • Wearables
  • Device Engineering
  • Human Factors
  • CMC
  • Injectables
  • Sterile Manufacturing
  • Packaging
  • Regulatory Affairs

Featured Speakers

  • Alexander Zuern,Device testing manager, Novartis International AG
  • Andrew Warrington, Project Leader & Patient Advocate, Novartis
  • Benjamin Werner,Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG
  • Bjorg K Hunter, Regulatory Manager, Devices, GSK
  • Blake Green, Senior Manager Regulatory Affairs, Amgen
  • Camille Dagallier, Formulation and Drug Process Development Senior Scientist, Sanofi
  • Christopher Muenzer, Senior Device Technology Manager, Novartis
  • Joel Richard,Head of Technical & Pharmaceutical Operations, MedinCell
  • Mark Palmer, Scientific Leader, Biopharm Device Engineering, GSK
  • Rebecca Moses, Director, Core Human Factors Inc.
  • Rupal Nguyen, Principal Engineer, Allergan
  • StefaniaRagone, Pharmaceutical Assessor, Medicines & Healthcare Products Regulatory Agency (MHRA)
  • Tina Arien, Principal Scientist, Janssen Pharmaceutica
  • Vikas Jaitely, Director, Global Regulatory Affairs Transitional Medicine and Devices, Merck

Early-bird rates

  • Book by 31st January and save £400
  • Book by 28th February and save £300
  • Book by 29th March and save £200

For further information and to register, please visit:
http://www.injectable-drug-delivery.com/wpnwl

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

NIH scientists build a cellular blueprint of multi…

Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms ...

Scientific evidence to date on COVID-19 vaccine ef…

An expert review by an international group of scientists, including some at the WHO and FDA, concludes that, even for the delta variant, vaccine efficacy against severe C...

How a plant virus could protect and save your lung…

Using a virus that grows in black-eyed pea plants, nanoengineers at the University of California San Diego developed a new treatment that could keep metastatic cancers at...

COVID-19 nasal vaccine candidate effective at prev…

Breathe in, breathe out. That’s how easy it is for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. And though remarkable progress has been made in develop...